

SCIENTIFIC PROGRAMME

- 08.15 – 08.30** **Registration**
- 08.30 – 08.40** **Opening**
Dr. García (Hospital U. Reina Sofia Manager) and *Dr. Briceño* (Head of Surgery, Hospital U. Reina Sofia)
- 08.40 – 09.00** **Welcome**
Prof. Rufian Peña (Hospital U. Reina Sofia, Spain) and *Dr. Kjersti Flatmark* (Oslo University Hospital, Norway)

Session 1: Diagnosis of PMP. Chairs: Dr Mohamed / Dr. Casado

- 09.00 – 09.15** **Diagnosis of PMP – Pathology**
How is PMP diagnosed? How is it classified, and why is it important to get the diagnosis and classification correct?
Dr. Norman Carr (Hampshire Hospitals NHS Trust, U.K.)
- 09.20 – 09.30** **Diagnosis of PMP – Radiology**
How are radiology and nuclear diagnostic techniques used to diagnose and classify PMP?
Dr. Martin (Hospital U. Reina Sofia, Spain)
- 09.30 – 09.40** **Diagnosis of PMP – Radiology II**
Radiological evaluation of the resectability of PMP
Dr. Andrew Thrower (Peritoneal Malignancy Institute, U.K.)
- 09.45 – 09.55** **Diagnosis of PMP – Molecular analysis**
Dr. Antonio Romero Ruiz (IMIBIC Research Institute, Spain)

Session 2: EuroPMP. Chairs: Dr. Barrios / Dr. Arjona

- 10.00 – 10.15** **The EuroPMP COST Action**
How the COST Action model works, who is involved and how is it managed. STSMs and other opportunities for ECI researchers.
Dr. Kjersti Flatmark (Oslo University Hospital, Norway)
- 10.20 – 10.35** **Standardising protocols - Why is it important?**
A short look into why protocol standardisation is important (comparability, sharing of data, sample sharing, etc.) and what the EuroPMP Action is doing to try to standardise protocols.
Dr. Norman Carr (Hampshire Hospitals NHS, U.K.)
- 10.40 – 11.00** **Coffee Break**
- 11.00 – 11.15** **Standards of Care Across Europe**
What is the standard of care around Europe right now? How can EuroPMP work to improve the care and outcomes for PMP patients?
Dr. Faheez Mohamed (Peritoneal Malignancy Institute, U.K.)
- 11.20 – 11.35** **Scientific Communication: What's the point?**
Why is it important to get the word out not just about major research findings, but also about treatment methods and care? How do we target the various levels of people so that everyone is able to get what they need, from a top scientist to a newly diagnosed patient? How is the EuroPMP COST Action helping to improve awareness of PMP in Europe?
Dr. Adrian Bartos (Regional Institute of Gastroenterology and Hepatology, Romania)
-

Session 3: Selected topics from PMP experimental research Chairs: Dr. Deraco / Dr. Rodriguez

- 11.40 – 11.55 Topic 1 How the different experimental models of PMP help us in its molecular characterization and treatment?
Dr. Karianne Giller Fleten (Institute for Cancer Research, Norway)
- 12.00 – 12.15 Topic 2 Targeting therapies, a necessary weapon in PMP management
Dr. Shigeki Kusamura (Fondazione IRCCS Istituto Nazionale Tumori di Milano, Italy)

Session 4: Early Career Investigators' Session Chairs: Dr. Flatmark / Dr. Romero

- 12.20 – 12.30 Bromelain combined with N-acetyl-cysteine as mucolytic agent to treat extensive and/or recurrent pseudomyxoma peritonei
Dr. Vahan Kepenekian (France)
- 12.35 – 12.45 A real-time ex-vivo model (eIBUB) for optimizing intraperitoneal drug delivery as an alternative to living animal models
Dr. Iaroslav Sautkin (Germany)
- 12.50 – 13.00 Hydroxamic acid analogs of Vorinostat as new potent cytotoxic agents
Christiana Mantzourani (Greece)
- 13.05 – 13.15 Novel therapeutic targets for pseudomyxoma peritonei
Dr. Christin Lund-Andersen (Norway)
- 13.20 – 13.30 Molecular characterization of pseudomyxoma peritonei and development of biomarkers and target therapies in a mouse model with human xenograft
Dr. Blanca Rufián Andújar (Spain)
- 13.30 – 14.30 Poster viewing and networking
- 14.30 – 15.30 **Lunch**

Session 5: Surgical Treatment of PMP Chairs: Dr. Bartos / Dr. Sanchez

- 15.30 – 16.30 **Treatment of PMP – surgery**
- 15.30 – 15.45 CRS-HIPEC
Dr. Pedro Barrios (Consoarci, Sanitari Integral - CCSI, Spain)
- 15.50 – 16.05 Role of minimally invasive approaches, is there a role for PIPAC?
Dr. Alvaro Arjona Sanchez (H.U. Reina Sofia, Spain)
- 16.10 – 16.25 Choosing the best drug for HIPEC in PMP
Dr. Marcello Deraco (Fondazione IRCCS Istituto Nazionale Tumori di Milano, Italy)
- 16.30 – 16.45 Unexpected appendiceal tumors
Dr. Shigeki Kusamura (Fondazione IRCCS Istituto Nazionale Tumori di Milano, Italy)
- 16.50 – 17.20 **Treatment of PMP after primary surgical management of PMP**
- 16.50 – 17.00 Systemic Treatment of PMP
Dr. Manuel Valladares (H.U. Reina Sofia, Spain)
- 17.05 – 17.20 What happens when primary treatment fails?
Dr. Marcello Deraco (Fondazione IRCCS Istituto Nazionale Tumori di Milano, Italy)
- 17.25 – 17.40 **Future directions in PMP**
Dr. Faheez Mohamed (Peritoneal Malignancy Institute, U.K.)
- 17.45 – 18.00 **Closing and take-home-messages**
Dr. Alvaro Arjona-Sanchez (H.U. Reina Sofia, Spain)

Endorsed by: